Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, expects to achieve important milestones in the year ahead. The company’s proprietary i/Blue Imaging System is designed to significantly enhance surgeons’ ability to visualize and remove cancer cells using blue light by combining advanced optics and light sensors with a contrast imaging agent. The system’s key feature is its adaptability to almost any scope already in use by hospitals and surgical centers. Despite the challenges of 2020, Imagin was able to transition its product from the development stage to manufacturing, contracting with FDA registered and ISO 13485:2016-certified manufacturer Lighthouse Imaging. The contract will assist to propel Imagin toward completion of its final pre-production stage and finalize test parameters that meet exacting FDA requirements for live-use surgical imaging equipment. “Our relationship with Lighthouse Imaging marks a new stage in the company’s progress,” Imagin President and CEO Jim Hutchens stated in a recent update. “We anticipate 2021 to be a breakout year with emphasis on manufacturing and the FDA process.”
To view the full article, visit https://ibn.fm/mrGz3
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.